ストックスクリーナーアプリを入手
4.40
0.23%
0.01
アフターアワーズ：
4.38
-0.02
-0.45%
前日終値:
$4.39
開ける：
$4.44
24時間の取引高:
497.75K
Relative Volume:
0.22
時価総額：
$866.53M
収益：
$14.08M
当期純損益:
$-33.50M
株価収益率:
-25.09
EPS:
-0.1754
ネットキャッシュフロー:
$-39.72M
1週間 パフォーマンス:
+6.02%
1か月 パフォーマンス:
-1.79%
6か月 パフォーマンス:
-4.56%
1年 パフォーマンス:
+25.36%
1日の値動き範囲:
$4.35
$4.54
1週間の範囲:
$4.01
$4.54
52週間の値動き範囲:
$2.94
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.40 | 864.57M | 14.08M | -33.50M | -39.72M | -0.1754 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey
Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo
ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus
FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus
Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus
Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseHere's Why - MarketBeat
Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart
ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - The Manila Times
[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Arbutus reports results, announces $2.25B Moderna settlement - MSN
ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo
Arbutus Reports Results, Announces $2.25B Moderna Settlement - MyChesCo
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
ABUS Should I Buy - Intellectia AI
ABUS PE Ratio & Valuation, Is ABUS Overvalued - Intellectia AI
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus: Q4 Earnings Snapshot - theheraldreview.com
Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox
Arbutus Biopharma earnings missed by $0.14, revenue topped estimates - investing.com
Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart
Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus
Arbutus: Fourth Quarter Financial Results Overview - Bitget
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):